期刊文献+

血清CA125及HE4水平对卵巢癌组织ERα表达的影响 被引量:2

The effects of serum CA125 and HE4 on the expression of estrogen receptorαon ovarian cancer tissues
下载PDF
导出
摘要 目的探讨卵巢癌患者血清CA125及雌激素(HE4)水平对卵巢癌组织雌激素受体α(ERα)表达的影响,为卵巢癌的临床诊断及抗雌激素治疗提供依据。方法收集50例卵巢癌患者手术前血清及手术后组织标本,化学发光法检测卵巢癌患者及正常对照组血清中CA125、HE4含量,免疫组织化学法标示卵巢癌组织中ERα表达状况;并用统计学软件SSPS19.0,比较卵巢癌组织ERα阳性与ERα阴性患者血清中CA125、HE4水平的差异,分析其与ERα表达的关系。结果卵巢癌患者血清CA125及HE4水平均高于正常对照组(P<0.001),且与临床分期有关(P<0.01)。卵巢癌组织ERα阳性与ERα阴性患者血清中CA125水平无明显差异(P=0.360);但HE4水平存在差异(P=0.024)。免疫组化染色显示,卵巢癌组织中ERα阳性率为56%,大多在细胞核表达;其表达水平与血清HE4含量呈负相关(r=0.852,P=0.031)。血清HE4水平相对较低的卵巢癌组织中ERα表达水平较高;而血清HE水平较高的卵巢癌组织中ERα在细胞核表达水平明显降低。结论血清CA125及HE4含量同时增高对卵巢癌诊断具有重要参考价值;血清HE4水平升高可影响ERα表达,其含量高低可为临床以ERα为靶标进行卵巢癌治疗提供依据。 Objective To explore the effects of serum CA125 and Human Epididymis Protein 4(HE4)on the expression of estrogen receptorα(ERα)on ovarian cancer tissues,and provide the basis for diagnosis and treatment of ovarian cancer.Methods The serum levels of CA125 and HE4in 20 cases of health control and 50 cases of patients with ovarian cancer before surgery were measured by chemilumineseent immunoassay(CLIA).The expression status of ERαon ovarian cancer tissues were detected by immunohistochemical staining.The difference of the serum levels of CA125 and HE4in ERαpositive and negative patients,and their relationship with ERαwere analyzed by SSPS 13.0software.Results Both of the serum levels of CA125 and HE4in ovarian cancer patients were higher than those in health control(P〈0.001),and related to ovarian cancer clinical stages(P〈0.01).Although the serum level of CA125 was no difference(P=0.360),the level of HE4 was difference in ERαpositive and negative patients(P=0.024).In ovarian cancer tissues,the majority of ERαwas expressed on ovarian epithelial nuclei,its positive rate was 56%.Compared with low level of serum HE4 patients,the nuclear staining for ERαin ovarian cancer tissue from high serum HE4 patients was reduced,and that a negative relationship was showed between the levels of ERαexpression on cancer tissues and serum HE4(r=0.852,P=0.031).Conclusions The serum levels of CA125 and HE4have an important reference value for diagnosis of ovarian cancer.Especially,due to the increasing of serum HE4 could influence the expression of ERαon ovarian cancer cells,the serum level of HE4 maybe served as an indicator for clinical treatment ovarian cancer using anti-estrogen drug or others targeting the overexpression ERα therapy.
出处 《滨州医学院学报》 2016年第1期9-12,共4页 Journal of Binzhou Medical University
关键词 人附睾蛋白4 CA125 雌激素受体Α 卵巢癌 CA125 HE4 ERα ovarian cancer
  • 相关文献

参考文献18

  • 1Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015 [J]. CA Cancer J Clin,2015,65(1) :5-29.
  • 2Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012[J]. CA Cancer J Clin. 2012,62(1) : 10-29.
  • 3Fraunhoffer NA, Meilerman Abuelafia A, Stella I, et al. Identification of germ cell-specific VASA and IFITM3 proteins in hu- man ovarian endometriosis[J]. J Ovarian Res, 2015,8 (1) : 66.
  • 4McSorley MA, Alberg A J, Allen DS, et al. Prediagnostie circulat- ing follicle stimulating hormone concentrations and ovarian canc- er risk[J]. Int J Cancer, 2009,125 (3) : 674-679.
  • 5Kessler M,Fotopoulou C,Meyer T. The molecular fingerprint of high grade serous ovarian cancer reflects its fallopian tube origin [J]. Int J Mol Sci,2013,14(4) :6571 -6596.
  • 6Nassir M,Guan J,Luketina H,et al. The role of HE4 for predic- tion of recurrence in epithelial ovarian cancer patients-results from the OVCAD study[J]. Tumour Biol, 2015, [Epub ahead of print].
  • 7Hellstrom I, Hellstrom KE. SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other[J], dv Exp Med Bid, 2008(622) : 15- 21.
  • 8Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass[J]. Gynecol Oncol, 2009,112(1) :40-46.
  • 9van de Weijer PH. Risks of hormone therapy in the 50-59 year age group[J]. Maturitas, 2008,60 (1) : 59-64.
  • 10Shapiro S. False alarm:postmenopausal hormone therapy and o- varian cancer[J]. Clirnacterie,2007,10(6) :466-469.

二级参考文献50

  • 1Moore RG,Mcmeekin DS,Brown AK,et al.A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.Gynecol Oncol,2009,112:40-46.
  • 2Hellstrom(o) I,Hellstrom KE SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other.Adv Exp Med Biol,2008,622:15-21.
  • 3Bast Jr RC,Feeney M,Lazarus H,et al.Reactivity of amonoclonal antibody with human ovarian carcinoma.J Clin Invest,1981,68:1331-1337.
  • 4Kabawat SE,Bast RC Jr,Bhan AK,et al.Tissue distribution of a coelomic epithelium-related antigen recognized by the monoclonal antibody OC 125.Int J Gynecol Pathol,1983,2:275-285.
  • 5Riedinger JM,wafnart J,Rieolleau G,et al.CA125 halflife and CA125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome:results of a French muhicemrie study.Annas of Oncology,2006,17:1234-1238.
  • 6Riedinger JM,Bonnetain F,Eche N,et al.Prognostic value of CA125 half-life and early normalization during chemotherapy in advanced ovarian tumors:results of a muhicentric.French study Bull Cancer,2007,94:287-295.
  • 7Kim HS,Park NH,Chung HH,et al.Serum CA125 levelafter 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responderK survival in patients with advanced epithelial ovarian cancer.Onkologie,2008,31:315-320.
  • 8Rustin GJ,Marples M,Nelstmp AE,et al.Use of CA125to define progression of ovarian cancer in patients with persistently elevated levels.J Clin Oncol,2001,19:4054-4057.
  • 9Nyvang GB,Mogensen O,Bichel P,et al.Combined prognostic importance of CA125,histopathologic grade and DNAindex in advanced ovarian cancer.Eur J Gynaecol Oncol,2000,21:569-572.
  • 10Low RN,Saleh F,Song SY,et al.Treated ovarian cancer:comparison of MR imaging with serum CA-125 level and physical examination-A longitudinal studyRadiology,1999,211:519-528.

共引文献52

同被引文献26

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部